ADMA:NSD-ADMA Biologics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.07

Change

-0.04 (-1.29)%

Market Cap

USD 0.26B

Volume

2.57M

Average Target Price

USD 12.50 (+307.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-7.25 (-3.23%)

USD57.85B 49.47 37.66
REGN Regeneron Pharmaceuticals, Inc

-2.78 (-0.61%)

USD49.46B 24.35 19.19
ALXN Alexion Pharmaceuticals, Inc

-2.13 (-2.47%)

USD19.07B 8.05 7.52
SGEN Seattle Genetics, Inc

-6.87 (-5.92%)

USD17.09B N/A -97.94
INCY Incyte Corporation

-4.09 (-5.60%)

USD14.95B 33.64 28.94
BMRN BioMarin Pharmaceutical Inc

-3.13 (-3.79%)

USD13.14B N/A 29,715.80
GMAB Genmab A/S

+0.09 (+0.45%)

USD12.83B N/A N/A
GLPG Galapagos NV

-5.35 (-2.85%)

USD11.88B 72.40 N/A
ALNY Alnylam Pharmaceuticals, Inc

-3.01 (-2.81%)

USD11.15B N/A -11.34
BGNE BeiGene, Ltd

-0.77 (-0.61%)

USD10.58B N/A -9.67

ETFs Containing ADMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.25% 58% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.25% 58% F 59% F
Trailing 12 Months  
Capital Gain -6.69% 69% D+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.69% 69% D+ 72% C-
Trailing 5 Years  
Capital Gain -66.45% 45% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.45% 44% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -8.21% 41% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.21% 40% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 41.64% 52% F 27% F
Risk Adjusted Return -19.73% 42% F 23% F
Market Capitalization 0.26B 56% F 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.74 21% F 14% F
Price / Cash Flow Ratio -3.38 52% F 76% C
EV/EBITDA -8.04 80% B- 86% B
Management Effectiveness  
Return on Equity -210.08% 13% F 5% F
Return on Invested Capital -48.60% 57% F 19% F
Return on Assets -23.98% 63% D 19% F
Debt to Equity Ratio 317.64% 8% F 6% F
Technical Ratios  
Short Ratio 2.54 62% D- 55% F
Short Percent 16.97% 19% F 17% F
Beta 2.83 6% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector